Clinical Trial Update: A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 open-label, multiple ascending dose study of DS-3078a, a TORC1/2 kinase inhibitor, in adults with advanced solid tumors or lymphoma; the trial has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• DS-3078a

Snippet

Sponsor: Daiichi Sankyo | Conditions: Advanced Solid Tumor, Lymphoma | Phase 1 | Status: COMPLETED